Irvine, Calif. (March 14, 2012) – PathCentral, Inc. (www.pathcentral.net), the first and only company focused exclusively on the success of the community pathologist, today announced the appointment of genomic pathologist and researcher Shelly Gunn, M.D., Ph.D. to the post of Associate Medical Director, Clinical Genomics.
Dr. Gunn is recognized as one of the world’s leading experts in the clinical application of array comparative genomic hybridization (aCGH) technology, specifically in the areas of breast cancer and hematologic malignancies. She is the founder and medical director for Oncopath Laboratory at the START Center for Cancer Care in San Antonio, Texas where she also previously served as assistant clinical professor in the Department of Pathology at the University of Texas Health Science Center, San Antonio (UTHSCSA). She has authored a number of abstracts and articles on the clinical application of aCGH and has been a featured guest speaker at scientific meetings and symposia across the U.S.
“We’re extremely excited that Dr. Gunn has joined the Clinical Genomics team at PathCentral,” said Todd S. Barry, M.D., Ph.D., PathCentral’s medical director. “Her deep knowledge and extensive experience in the clinical application of array CGH adds a powerful new resource to our program and will help make our technology and service offerings even more robust for our community pathologist customers.”
“PathCentral has assembled an impressive team of technical, clinical, and medical experts to build and grow a world-class clinical genomics center of excellence,” said Dr. Gunn. “I’m proud to be part of this team that will help transform the way the clinical community harnesses the power of technologies like array CGH.”
Dr. Gunn graduated with a combined M.D./Ph.D. degree from the UTHSCSA Medical School and Graduate School of Biomedical Sciences with a focus in diagnostic molecular genetics, and also completed her clinical pathology residency at UTHSCSA. She’s a recipient of the Association for Molecular Pathology’s Young Investigator Award for outstanding translational research, and the UTHSCSA Klein Award for excellence in pathology. Her current clinical focus is the delivery of personalized care to cancer patients through the application of novel and powerful genetic and genomic technologies.
For more information on PathCentral, please visit www.pathcentral.net or call 888/516-4958.
About PathCentral, Inc.
PathCentral’s mission is to help community-based pathology practices increase revenue, reduce operating costs, and become more competitive in their local markets. The company has developed a proprietary web-based laboratory information system (LIS) that seamlessly integrates the essential components of a pathology practice’s day-to-day operations onto a single platform. The system utilizes the latest information technology tools, including an open-web service layer, which enables it to easily and seamlessly connect with hospitals, physicians’ offices, billing companies, and a wide variety of laboratory instrumentation. The company also has a full-service esoteric anatomic pathology reference laboratory and offers a broad range of cancer diagnostic testing services to its customers. The company is based in Irvine, Calif.